Drugs / Autologous Monocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02948426 | Feb 2017 → Sep 2020 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Monocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02948426 ↗ |
| Modality | Cell therapy | “The autologous monocytes cell product in 250ml total volume of investigational combination” NCT02948426 ↗ |
| Route | Other | “administered intraperitoneally once every 28 days” NCT02948426 ↗ |